[1] CARET R M, CALHOUN D A, BAKRIS G L, et al. Resistant hypertension: detection, evaluation, and management: a scientific statement from the American Heart Association[J]. Hypertension, 2018, 72(5):e53-e90.
[2] WILLIAMSON J D, SUPIANO M A, APPLEGATRE W B, et al. Intensive vsstandard blood pressure control and cardiovascular disease outcomes in adults aged ≥75 years: A Randomized Clinical Trial[J]. JAMA, 2016, 315(24):2673-2682.
[3] 李静, 范利, 华琦, 等. 中国老年高血压管理指南2019[J]. 中华高血压杂志, 2019, 27(2):111-135.
[4] COSTAS T, GIANFRANCO P, ALBERTO Z. Effects of blood-pressure-lowering treatment on outcome incidence in hypertension. 11. Effects of total cardiovascular risk and achieved blood pressure: overview and meta-analyses of randomized trials[J]. J Hypertens, 2017, 35(11):2138-2149.
[5] KITAGAWA K, YAMAMOTO Y, ARIMA H, et al. Effect of standard vs intensive blood pressure control on the risk of recurrent stroke: a randomized clinical trial and meta-analysis[J]. JAMA Neurol, 2019, 76(11):1309-1318.
[6] FU L, LI Y N, LUO D, et al. Evidence on the causal link between homocysteine and hypertension from a meta-analysis of 40 173 individuals implementing Mendelian randomization[J]. J Clin Hypertens: Greenwich, 2019, 21(12):1879-1894.
[7] DRAGAN D, VLADIMIR J, VLADIMIR Z, et al. Homocysteine and homocysteine-related compounds: an overview of the roles in the pathology of the cardiovascular and nervous systems[J]. Can J Physiol pharmacol, 2018, 96(10):991-1003.
[8] RANTANEN A T, KORKEILA J J A, LÖYTTYNIEMI E S, et al. Awareness of hypertension and depressive symptoms: a cross-sectional study in a primary care population[J]. Scand J Prim Health Care, 2018, 36(3):323-328. |
